Breast Cancer Clinical Trial

Single Dose Partial Breast Radiotherapy

Summary

This study seeks to determine the maximum tolerated dose of a single-dose partial breast radiation given before lumpectomy using a radiosurgery technique. Lumpectomy will be performed within 3 weeks (+/- 1 week) of completing radiation.

View Full Description

Full Description

This study will assess the safety of partial breast radiosurgery as measured by the incidence of acute toxicity and wound healing complications in three dose cohorts.

Patients will be enrolled in cohorts of 8 patients starting at dose level 1 (15 Gy). If 2 or more dose limiting toxicities (DLTs) are observed at dose level 1, the trial will be stopped for evaluation and consideration of revision. If at most one DLT is observed then escalation continues to the next dose level. The cohorts will escalate by 3Gy up to 21 Gy of irradiation.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Women with a biopsy proven diagnosis of low/intermediate grade ductal carcinoma in situ or invasive ductal (or other favorable histology) carcinoma of the breast
Breast preservation candidates (no prior breast or nodal radiotherapy, no imaging evidence of multicentric or multifocal disease, no pregnant women, and no comorbid conditions precluding surgery)
Clinical T1N0M0
55 years of age or older
Estrogen receptor (ER) positive,
No evidence of lymphovascular space invasion on initial biopsy
Not pregnant. If not post-menopausal must adhere to birth control measures
White blood cell count > 3000, Hemoglobin > 9, platelets >100000
Must be eligible for MRI on initial evaluation and GFR at least 60 ml/min

Exclusion Criteria:

Neoadjuvant chemotherapy
Breast implants
Medical conditions that may increase risk for poor cosmetic outcome (i.e. Lupus, rheumatoid arthritis, scleroderma)
Patients unable to receive study treatment planning secondary to body habitus or inability to lie flat on the stomach at length
HER-2/neu positive
Positive serum pregnancy test

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

35

Study ID:

NCT00944528

Recruitment Status:

Active, not recruiting

Sponsor:

Duke University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Duke University Medical Center
Durham North Carolina, 27710, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

35

Study ID:

NCT00944528

Recruitment Status:

Active, not recruiting

Sponsor:


Duke University

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider